Immunorestoration Immunosenescence, in its dysregulation of cellular immune functions, weakens the body’s ability to limit Carcinogenesis to its non-pathologic phases. In this state of dysregulation the cells of the immune system not only fail to effectively eliminate pre-cancerous cells, but also act to promote their transformation and proliferation as a result of inflammatory dysregulation. Immunorestoration— the restoration of immune system cancer-killing activity via persistent reversal of Immunosenescence— thus emerges as a strategy. The optimal focus for intervention in any complex process is the common,
rate-limiting step or phase. With respect to Carcinogenesis, it is clear that the critical step is that point on the pathway where initiated
cells and metastatic cells lay dormant, evading immune surveillance, awaiting activation to grow into a malignancy. Immunity Against Carcinogenesis—Spontaneous Regression of Malignancies The spontaneous regression of human malignancy has been documented in the literature, but is considered to be of an unreliable frequency. Recent breakthrough in vivo studies in mice, however, describe the presence of naturally-occurring, leukocyte-dependent immunity, and offer a possible mechanism for spontaneous regression [8]. These mice demonstrate both spontaneous regression (SR) of existing tumors, and complete resistance (CR) to tumor induction by inoculation with cancer cells. As well, when specific types of innate immune cells (including NK cells) from SR/CR mice are transfused into normal mice with existing tumors, their cancer is eradicated [9]. What was discovered was that the SR/CR immune cells can migrate to the site of a tumor and selectively eliminate the cancer cells without damaging the surrounding normal tissues. The findings have been extrapolated to humans for evaluation under an IND in an FDA-approved clinical trial protocol involving pooled-donor leukocyte transfusions to cancer patients with diminished immunity. Immunity Against Carcinogenesis— Allotypic Immunomodulation Specific activity of AIM Immunorestoration has been demonstrated in vitro and in vivo to modulate NK and other immune cell activity in a manner suited to the reversal of Immunosenescence and control of Carcinogenesis [10]. We have found that RBAC, a prototype arabinoxylan oligosaccharide Allotypic Immunomodulator (AIM) derived from Oryza sativa L., optimizes innate immune cell cancer-killing activity in a dose-dependent manner via oral administration [11]. This has further been corroborated in a clinical case report in which RBAC administration led to a complete tumor regression and remission in a patient with documented Metastatic Hemangiopericytoma [12]. We therefore propose that the demonstrated immunorestorative activity of RBAC represents a strategy of significant
potential in the therapeutic control of Carcinogenesis via eradication of transformed cells at the initiation
or pre-cancerous stage, as well as the pre-clinical and clinical stages of malignant promotion and proliferation. References
|
